Author

René Meisner

Denali Therapeutics (United States)ORCID 0000-0002-3246-9140Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Adam P. SilvermaniD· 1 shared Allisa J. Clemens· 1 shared Amy Wing-Sze Leung· 1 shared Ana Claudia Silva AmaraliD· 1 shared Claire B. DiscenzaiD· 1 shared Darren Chan· 1 shared David A. JoyiD· 1 shared Do Jin KimiD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperNeuroscience

Adam P. SilvermanORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Engineering anti-amyloid antibodies with transferrin receptor targeting improves brain biodistribution and mitigates ARIA

Michelle E. Pizzo, Edward D. Plowey, Nathalie Khoury, Wanda Kwan, Jordan Abettan, Sarah L. DeVos, Claire B. Discenza, Timothy Earr, David A. Joy, Ming Lye‐Barthel, Elysia Roche, Darren Chan, Jason C. Dugas, Kapil G. Gadkar, René Meisner, , Y. Joy Yu Zuchero

This study develops an antibody transport vehicle targeting the transferrin receptor to improve brain delivery of anti-amyloid antibodies, reducing ARIA-like lesions and vascular inflammation in a mouse model.

bioRxiv · Jul 26, 2024 · PreprintNeuroscience